Design Therapeutics (DSGN) Net Margin (2020)

Design Therapeutics (DSGN) reported Net Margin of 11736.36% for Q4 2020, up 1.5% sequentially from 11915.0% in Q3 2020.

Design Therapeutics (DSGN) Net Margin (2020) Analysis & Trends

Design Therapeutics (DSGN) has 1 years of Net Margin data on file, last reported at 11736.36% in Q4 2020.

For the quarter ending Q4 2020, Net Margin changed N/A year-over-year to 11736.36%; the trailing twelve-month figure through Dec 2020 stood at 3699.12% (changed N/A YoY), and the FY2020 full-year result was 7609.73%, changed N/A from the prior year.
Net Margin improved to 11736.36% in Q4 2020, from 11915.0% in the prior quarter.
In the past five years, Net Margin ranged from a high of 451.41% in Q1 2020 to a low of 11915.0% in Q3 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	15.02%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	34.53%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	20.17%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	30.33%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Design Therapeutics	714.48 Mn	491.66 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2020	-11,736.36%
Sep 30, 2020	-11,915.00%
Jun 30, 2020	-4,719.35%
Mar 31, 2020	-451.41%